Community awareness and misconceptions regarding GLP-1 receptor agonists for weight management among adults in the Aseer Region, Saudi Arabia: a cross-sectional study
Abstract
BackgroundGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for diabetes and obesity management. Growing interest in their use for weight management has raised concerns regarding gaps in knowledge and misconceptions about their indications, safety, and appropriate use. This study assessed awareness, knowledge, misconceptions, and associated sociodemographic and clinical factors among adults in the Aseer Region, Saudi Arabia.MethodsA cross-sectional survey was conducted among 975 adults aged ≥18 years in the Aseer Region, Saudi Arabia, using convenience sampling. A structured Arabic questionnaire assessed GLP-1 RA awareness, knowledge, perceived uses, information sources, and misconceptions. Descriptive statistics, chi-square tests, and multivariable logistic regression were used to examine factors associated with knowledge and semaglutide awareness.ResultsAmong 975 participants, semaglutide was the most recognized GLP-1 RA, with 576 (59.1%) reporting awareness, while 507 (52.0%) identified GLP-1 RAs as being used for both diabetes and weight loss. Overall, 519 (53.2%) participants had good knowledge, with considerable uncertainty and misconceptions regarding safety, adverse effects, monitoring, and lifestyle modification. In multivariable analysis, all age groups ≥30 years had lower odds of good knowledge than those aged 18–29 years (aORs 0.24–0.36). For semaglutide awareness, participants aged ≥60 years had lower odds (aOR 0.145, 95% CI: 0.078–0.270), whereas females had higher odds than males (aOR 1.973, 95% CI: 1.452–2.679), and graduates had higher odds than those with school-level education (aOR 2.552, 95% CI: 1.576–4.134).ConclusionThis study identified important gaps and misconceptions regarding GLP-1 receptor agonists among adults in the Aseer Region. Although 53.2% demonstrated good knowledge, uncertainty remained regarding safety, adverse effects, monitoring, and lifestyle modification. Age ≥30 years was associated with lower odds of good knowledge, while female sex and graduate-level education were associated with higher odds of semaglutide awareness. These findings highlight the need for targeted, evidence-based education on the appropriate and safe use of GLP-1 receptor agonists.
Related
- Dementia knowledge, risk reduction awareness, misconceptions, and stigma in Kuwait: a cross-sectional study
- Awareness, Misconceptions, and Cultural Beliefs About Functional Neurological Disorders: A Cross-Sectional Study
- Community Awareness, Utilization, and Factors Influencing the Use of Over-the-Counter Scar Management Products: A Cross-Sectional Survey
- Comparative Evaluation of Large Language Models in Responding to Common Misconceptions Regarding Periodontal Disease and Oral Hygiene
- Public Knowledge, Attitudes, and Preventive Practices Regarding Mpox in Bangladesh: Insights From a Community‐Based Cross‐Sectional Survey
BibTeX
@article{alshahrani2026community,
title = {{Community awareness and misconceptions regarding GLP-1 receptor agonists for weight management among adults in the Aseer Region, Saudi Arabia: a cross-sectional study}},
author = {Asma M. Alshahrani and Geetha Kandasamy and Sitah Alharthi and Vasudevan Mani and Kousalya Prabahar},
journal = {Frontiers in Public Health},
year = {2026},
month = oct,
doi = {10.3389/fpubh.2026.1978025},
url = {https://www.frontiersin.org/articles/10.3389/fpubh.2026.1978025},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Community awareness and misconceptions regarding GLP-1 receptor agonists for weight management among adults in the Aseer Region, Saudi Arabia: a cross-sectional study
AU - Asma M. Alshahrani
AU - Geetha Kandasamy
AU - Sitah Alharthi
AU - Vasudevan Mani
AU - Kousalya Prabahar
PY - 2026
DA - 2026/10/30
JO - Frontiers in Public Health
DO - 10.3389/fpubh.2026.1978025
UR - https://www.frontiersin.org/articles/10.3389/fpubh.2026.1978025
AB - BackgroundGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for diabetes and obesity management. Growing interest in their use for weight management has raised concerns regarding gaps in knowledge and misconceptions about their indications, safety, and appropriate use. This study assessed awareness, knowledge, misconceptions, and associated sociodemographic and clinical factors among adults in the Aseer Region, Saudi Arabia.MethodsA cross-sectional survey was conducted among 975 adults aged ≥18 years in the Aseer Region, Saudi Arabia, using convenience sampling. A structured Arabic questionnaire assessed GLP-1 RA awareness, knowledge, perceived uses, information sources, and misconceptions. Descriptive statistics, chi-square tests, and multivariable logistic regression were used to examine factors associated with knowledge and semaglutide awareness.ResultsAmong 975 participants, semaglutide was the most recognized GLP-1 RA, with 576 (59.1%) reporting awareness, while 507 (52.0%) identified GLP-1 RAs as being used for both diabetes and weight loss. Overall, 519 (53.2%) participants had good knowledge, with considerable uncertainty and misconceptions regarding safety, adverse effects, monitoring, and lifestyle modification. In multivariable analysis, all age groups ≥30 years had lower odds of good knowledge than those aged 18–29 years (aORs 0.24–0.36). For semaglutide awareness, participants aged ≥60 years had lower odds (aOR 0.145, 95% CI: 0.078–0.270), whereas females had higher odds than males (aOR 1.973, 95% CI: 1.452–2.679), and graduates had higher odds than those with school-level education (aOR 2.552, 95% CI: 1.576–4.134).ConclusionThis study identified important gaps and misconceptions regarding GLP-1 receptor agonists among adults in the Aseer Region. Although 53.2% demonstrated good knowledge, uncertainty remained regarding safety, adverse effects, monitoring, and lifestyle modification. Age ≥30 years was associated with lower odds of good knowledge, while female sex and graduate-level education were associated with higher odds of semaglutide awareness. These findings highlight the need for targeted, evidence-based education on the appropriate and safe use of GLP-1 receptor agonists.
SN - 2296-2565
ER -